adenosine A3 receptor antagonists

Preferred Label : adenosine A3 receptor antagonists;

MeSH definition : Compounds that selectively bind to and block the activation of ADENOSINE A3 RECEPTORS.;

Is substance : O;

action pharmacologique : O;

Détails

Origin ID

D058918;

UMLS CUI

C2936573;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Indexing information
- 2-(6-amino-2-(hex-1-enyl)-9H-purine-9-yl)tetrahydrothiophene-3,4-diol [MeSH Supplementary Concept]
- 2-(6-amino-2-(hex-1-ynyl)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol [MeSH Supplementary Concept]
- 4-methoxy-N-(4-benzylamino-3-cyanoquinolin-2-yl)benzamide [MeSH Supplementary Concept]
- N-(1-(cyclohexylmethyl)piperidin-4-yl)-N'-(2-(2-furyl)-8-methyl-8H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-yl)urea [MeSH Supplementary Concept]
MeSH Descriptor(s) used for indexing
- receptor, adenosine a3 [MeSH Descriptor]
Record concept(s)
- adenosine A3 receptor antagonists [MeSH concept]
See also (suggested by CISMeF)
- receptor, adenosine a3 [MeSH Descriptor]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- 1-benzyl-7-methyl-3-propyl-1H,8H-imidazo(2,1-f)purine-2,4-dione [MeSH Supplementary Concept]
- 2-(4-methoxyphenyl)-1,2,4-triazolo(1,5-a)quinoxalin-4-one [MeSH Supplementary Concept]
- 2-(4-nitrophenyl)-1,2,4,5-tetrahydro-1,2,4-triazolo(4,3-a)quinoxaline-1,4-dione [MeSH Supplementary Concept]
- 4-benzoylamino-2-(4-methoxyphenyl)pyrido(2,3-e)-1,2,4-triazolo(4,3-a)pyrazin-1-one [MeSH Supplementary Concept]
- 4-dibenzoylamino-2-(4-methoxyphenyl)pyrazoloquinoline [MeSH Supplementary Concept]
- 4-diphenylacetylamino-2-phenylpyrazoloquinoline [MeSH Supplementary Concept]
- 9-chloro-2-(2-furyl)-5-phenylacetylamino(1,2,4)triazolo(1,5-c)quinazoline [MeSH Supplementary Concept]
- 9-chloro-5-(4-methoxybenzoyl)amino-2-phenyl(1,2,3)triazolo(1,2-a)(1,2,4)benzotriazin-1-one [MeSH Supplementary Concept]
- LJ-2698 [MeSH Supplementary Concept]
- N-(2-(phenyl)-8-methylpyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-5-yl)phenylacetamide [MeSH Supplementary Concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients